These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31810310)

  • 61. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
    Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Valter I; Fitzpatrick LA; Riis BJ; Christiansen C; Bilezikian JP; Black D
    Mayo Clin Proc; 2017 Feb; 92(2):200-210. PubMed ID: 28160873
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cytarabine delivered by CD44 and bone targeting redox-sensitive liposomes for treatment of acute myelogenous leukemia.
    Wu H; Gao Y; Ma J; Hu M; Xia J; Bao S; Liu Y; Feng K
    Regen Biomater; 2022; 9():rbac058. PubMed ID: 36110161
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Local drug delivery of alendronate gel for the treatment of patients with chronic periodontitis with diabetes mellitus: a double-masked controlled clinical trial.
    Pradeep AR; Sharma A; Rao NS; Bajaj P; Naik SB; Kumari M
    J Periodontol; 2012 Oct; 83(10):1322-8. PubMed ID: 22264208
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.
    Allen MR; Burr DB
    J Bone Miner Res; 2007 Nov; 22(11):1759-65. PubMed ID: 17663638
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hyaluronic acid based nanocrystals hydrogels for enhanced topical delivery of drug: A case study.
    Wei S; Xie J; Luo Y; Ma Y; Tang S; Yue P; Yang M
    Carbohydr Polym; 2018 Dec; 202():64-71. PubMed ID: 30287044
    [TBL] [Abstract][Full Text] [Related]  

  • 66. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
    Bone HG; Cosman F; Miller PD; Williams GC; Hattersley G; Hu MY; Fitzpatrick LA; Mitlak B; Papapoulos S; Rizzoli R; Dore RK; Bilezikian JP; Saag KG
    J Clin Endocrinol Metab; 2018 Aug; 103(8):2949-2957. PubMed ID: 29800372
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
    Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
    J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Novel Enhanced Therapeutic Efficacy of Dapoxetine HCl by Nano-Vesicle Transdermal Gel for Treatment of Carrageenan-Induced Rat Paw Edema.
    Salem HF; Nafady MM; Kharshoum RM; Abd El-Ghafar OA; Farouk HO
    AAPS PharmSciTech; 2020 Apr; 21(3):113. PubMed ID: 32291553
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effect of the local delivery of alendronate on human adipose-derived stem cell-based bone regeneration.
    Wang CZ; Chen SM; Chen CH; Wang CK; Wang GJ; Chang JK; Ho ML
    Biomaterials; 2010 Nov; 31(33):8674-83. PubMed ID: 20719378
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hyaluronic acid modified nanostructured lipid carriers for transdermal bupivacaine delivery: In vitro and in vivo anesthesia evaluation.
    Yue Y; Zhao D; Yin Q
    Biomed Pharmacother; 2018 Feb; 98():813-820. PubMed ID: 29571251
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model.
    Hayami T; Pickarski M; Wesolowski GA; McLane J; Bone A; Destefano J; Rodan GA; Duong LT
    Arthritis Rheum; 2004 Apr; 50(4):1193-206. PubMed ID: 15077302
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Positive effect of alendronate on bone turnover in ovariectomised rats' osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration.
    Boche M; Pokharkar V
    Drug Deliv Transl Res; 2018 Oct; 8(5):1078-1089. PubMed ID: 29987552
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 74. 1% alendronate gel as local drug delivery in the treatment of Class II furcation defects: a randomized controlled clinical trial.
    Pradeep AR; Kumari M; Rao NS; Naik SB
    J Periodontol; 2013 Mar; 84(3):307-15. PubMed ID: 22554293
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.
    Turbí C; Herrero-Beaumont G; Acebes JC; Torrijos A; Graña J; Miguélez R; Sacristán J; Marín F
    Clin Ther; 2004 Feb; 26(2):245-56. PubMed ID: 15038947
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transdermal Drug Delivery System of Linagliptin Sustained-release Microparticle Gels: In vitro Characterization and In vivo Evaluation.
    Liu J; Guo S; Hong S; Piao J; Piao M
    Curr Drug Deliv; 2024 Jan; ():. PubMed ID: 38243939
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
    Recker R; Lips P; Felsenberg D; Lippuner K; Benhamou L; Hawkins F; Delmas PD; Rosen C; Emkey R; Salzmann G; He W; Santora AC
    Curr Med Res Opin; 2006 Sep; 22(9):1745-55. PubMed ID: 16968578
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate.
    Williams DS; McCracken PJ; Purcell M; Pickarski M; Mathers PD; Savitz AT; Szumiloski J; Jayakar RY; Somayajula S; Krause S; Brown K; Winkelmann CT; Scott BB; Cook L; Motzel SL; Hargreaves R; Evelhoch JL; Cabal A; Dardzinski BJ; Hangartner TN; Duong LT
    Bone; 2013 Oct; 56(2):489-96. PubMed ID: 23806798
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats.
    Zhao J; Li Y; Zhang H; Shi D; Li Q; Meng Y; Zuo L
    J Bone Miner Metab; 2019 Sep; 37(5):805-814. PubMed ID: 30706148
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
    Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.